Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (28)

2024

  1. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919

  2. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 6

2023

  1. Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV

    Biomedicine and Pharmacotherapy, Vol. 162

  2. HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART

    Journal of Medical Virology, Vol. 95, Núm. 7

  3. MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected

    Journal of Molecular Medicine, Vol. 101, Núm. 11, pp. 1409-1420

  4. Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  5. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

2022

  1. Dynamics of HIV Reservoir and HIV‐1 Viral Splicing in HCV‐Exposed Individuals after Elimination with DAAs or Spontaneous Clearance

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  2. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

    Biomedicine and Pharmacotherapy, Vol. 145

  3. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. Different HCV exposure drives specific miRNA profile in PBMCS of HIV patients

    Biomedicines, Vol. 9, Núm. 11

  2. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals

    Liver International, Vol. 41, Núm. 12, pp. 2885-2891

2020

  1. Hepatitis C virus influences HIV-1 viral splicing in coinfected patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-18

  2. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility after Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016

    Open Forum Infectious Diseases, Vol. 7, Núm. 12

  3. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIda 9416 study

    PLoS ONE, Vol. 14, Núm. 12

  2. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

    Scientific Reports, Vol. 9, Núm. 1

  3. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2018

  1. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings

    Hepatology, Vol. 68, Núm. 1, pp. 32-47

  2. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

    PLoS ONE, Vol. 13, Núm. 6